Factor v Leiden mutation in severe infection and sepsis

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 955-960

  Levi, Marcel ^a   Schouten, Marcel ^a   Van'T Veer, Cees ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

coagulation; Factor V Leiden; infection; sepsis; thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EXPERIMENTAL STUDY; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; MORTALITY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEPSIS; THROMBOPHILIA;

ANIMALS; FACTOR V; HUMANS; INFECTION; MICE; MUTATION; SEPSIS; THROMBOPHILIA;

EID: 84555170236     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297374     Document Type: Article

References (59)

1. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004 124 5 567-576 (Pubitemid 38297089)
2. Levi M. Disseminated intravascular coagulation: a disease-specific approach. Semin Thromb Hemost 2010 36 4 363-365
3. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999 341 8 586-592 (Pubitemid 29384168)
4. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010 36 4 367-377
5. Levi M, Marder V J. Coagulation abnormalities in sepsis. In: Colman R W. Marder V J. Clowes A W. George J N. Goldhaber SZ eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia Lippincott William and Wilkins 2006 1601-1613
6. Wheeler A P., Bernard G R. Treating patients with severe sepsis. N Engl J Med 1999 340 3 207-214 (Pubitemid 29063218)
7. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003 16 1-2 43-47 (Pubitemid 38477222)
8. Levi M, Keller T T., van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003 60 1 26-39 (Pubitemid 38373473)
9. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010 38 2, Suppl S26-S34
10. Anas A A., Wiersinga W J., de Vos A F., van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010 68 4 147-152
11. Robboy S J., Major M C., Colman R W., Minna J D. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol 1972 3 3 327-343
12. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983 107 10 543-547 (Pubitemid 13008611)
13. Coalson J J. Pathology of sepsis, septic shock, and multiple organ failure. In: Sibbald WJ, ed. Perspective on Sepsis and Septic Shock. Fullerton, CA Society of Critical Care Medicine 1986 27-59
14. Levi M. The coagulant response in sepsis. Clin Chest Med 2008 29 4 627-642 viii viii
15. Creasey A A., Chang A C., Feigen L, Wün T C., Taylor FBJ Jr, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993 91 6 2850-2860 (Pubitemid 23182545)
16. Kessler C M., Tang Z, Jacobs H M., Szymanski L M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997 89 12 4393-4401 (Pubitemid 27260249)
17. Taylor FBJ Jr, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991 33 3 127-134
18. Taylor FBJ Jr, Chang A, Esmon C T., D'Angelo A, Vigano-D'Angelo S, Blick K E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987 79 3 918-925 (Pubitemid 17050920)
19. Welty-Wolf K E., Carraway M S., Miller D L. et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001 164 10 Pt 1 1988-1996 (Pubitemid 33152340)
20. Miller D L., Welty-Wolf K, Carraway M S. et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002 26 6 650-658 (Pubitemid 34557365)
21. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992 101 3 816-823
22. Dhainaut J F., Yan S B., Joyce D E. et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004 2 11 1924-1933 (Pubitemid 40192745)
23. Levi M, Löwenberg E C. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008 34 5 417-424
24. Vanderschueren S, De Weerdt A, Malbrain M et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000 28 6 1871-1876 (Pubitemid 30428745)
25. Levi M M., Eerenberg E, Löwenberg E, Kamphuisen P W. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010 68 2 68-76
26. Löwenberg E C., Meijers J C., Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010 68 6 242-251
27. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007 33 6 563-572 (Pubitemid 47429308)
28. Inbal A, Kenet G, Zivelin A et al. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 1997 77 6 1086-1089 (Pubitemid 27311974)
29. Dogan Y, Aygun D, Yilmaz Y et al. Severe protein S deficiency associated with heterozygous factor V Leiden mutation in a child with purpura fulminans. Pediatr Hematol Oncol 2003 20 1 1-5 (Pubitemid 36033618)
30. al-Ismail S, Collins P, Najib R, James-Ellison M, O'Hagan M. Postinfection purpura fulminans in a patient heterozygous for prothrombin G20210A and acquired protein S resistance. Pediatr Hematol Oncol 1999 16 6 561-564 (Pubitemid 29519471)
31. Woods C R., Johnson C A. Varicella purpura fulminans associated with heterozygosity for factor V leiden and transient protein S deficiency. Pediatrics 1998 102 5 1208-1210 (Pubitemid 28511732)
32. Saçkesen C, Seçmeer G, Gürgey A et al. Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans. Pediatr Infect Dis J 1998 17 1 87 (Pubitemid 28086335)
33. Hofstra J J., Schouten M, Levi M. Thrombophilia and outcome in severe infection and sepsis. Semin Thromb Hemost 2007 33 6 604-609 (Pubitemid 47429313)
34. Texereau J, Pene F, Chiche J D., Rousseau C, Mira J P. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004 32 5, Suppl S313-S319
35. Mesters R M., Mannucci P M., Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. [see comments]. Blood 1996 88 3 881-886 (Pubitemid 26333310)
36. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008 34 8 742-746
37. Minnema M C., Chang A C., Jansen P M. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 95 4 1117-1123 (Pubitemid 30099813)
38. Yanada M, Kojima T, Ishiguro K et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002 99 7 2455-2458 (Pubitemid 34525432)
39. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001 29 7, Suppl S90-S94 (Pubitemid 32681588)
40. Bernard G R., Vincent J L., Laterre P F. et al, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 10 699-709 (Pubitemid 32204987)
41. Lay A J., Liang Z, Rosen E D., Castellino F J. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest 2005 115 6 1552-1561 (Pubitemid 40814663)
42. Jalbert L R., Rosen E D., Moons L et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998 102 8 1481-1488 (Pubitemid 28492214)
43. Levi M, Dörffler-Melly J, Reitsma P H. et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 2003 101 12 4823-4827 (Pubitemid 36857741)
44. Levi M, van der Poll T, Büller H R. Bidirectional relation between inflammation and coagulation. Circulation 2004 109 22 2698-2704 (Pubitemid 38737913)
45. Lay A J., Donahue D, Tsai M J., Castellino F J. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007 109 5 1984-1991 (Pubitemid 46348196)
46. Ganopolsky J G., Castellino F J. A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 2004 165 4 1433-1446 (Pubitemid 39297747)
47. Kondaveeti S, Hibberd M L., Booy R, Nadel S, Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999 18 10 893-896 (Pubitemid 29487510)
48. Kerlin B A., Yan S B., Isermann B H. et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003 102 9 3085-3092 (Pubitemid 37314741)
49. Schouten M, van't Veer C, Roelofs J J., Levi M, van der Poll T. Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study. Crit Care 2010 14 4 R145
50. Brüggemann L W., Schoenmakers S H., Groot A P., Reitsma P H., Spek C A. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006 34 8 2201-2206 (Pubitemid 44305626)
51. Schouten M, van der Sluijs K F., Roelofs J J., Levi M, Van't Veer C, van der Poll T. Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza. Eur Respir J 2010 36 6 1346-1354
52. Elmas E, Suvajac N, Jilma B, Weiler H, Borggrefe M, Dempfle C E. Factor V Leiden mutation enhances fibrin formation and dissolution in vivo in a human endotoxemia model. Blood 2010 116 5 801-805
53. Bernard G R., Margolis B D., Shanies H M. et al, Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004 125 6 2206-2216 (Pubitemid 38788191)
54. Yan S B., Nelson D R. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004 32 5, Suppl S239-S246
55. Benfield T L., Dahl M, Nordestgaard B G., Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 2005 192 10 1851-1857 (Pubitemid 41587840)
56. Benfield T, Ejrnaes K, Juul K et al. Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study. Crit Care 2010 14 2 R28
57. Tsantes A E., Tsangaris I, Bonovas S et al. The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. Blood Coagul Fibrinolysis 2010 21 2 175-181
58. Adamzik M, Frey U H., Riemann K et al. Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Crit Care Med 2008 36 6 1776-1779
59. Weiler H, Kerlin B, Lytle M C. Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 2004 32 5, Suppl S233-S238